

18th Annual Conference BHIVA April 2012

Why do patients switch therapy?

Alison Boyle, Sonali Sonecha, Sundhiya
Mandalia, Mark Nelson



Chelsea and Westminster Hospital 
NHS Foundation Trust

Background

- Despite improvements in ARV therapy, many patients still change regimens
- Previous study in our HIV cohort (2006) predicted annual switch rate of 20%

Purpose of this study

- Determine rate and reasons why patients switch
- Identify which ARVs are commonly implicated in toxicity switches



Chelsea and Westminster Hospital 
NHS Foundation Trust


Methods

- All patients who switched ARVs during an 18 month period (1st December 2009 and 31st May 2011)
- Reasons why patients switched were investigated
- Toxicity/adverse events recorded and which ARV was potential cause

Results


- 6211 pts on ARVs over 18 month period
- 923 regimens switched in 722 pts (12%)
→ 17% of switchers on treatment \leq 6 months
- Annual switch rate of 8% cf 20% in 2006

Reasons for switching ARVs




Toxicity switches

- 452 switches due to toxicity/perceived toxicity



Observed Toxicity Switch Ratio (OTSR) per 1000 patient years (95% CI)

(2006 data shown in table)



Conclusions

- Rate of switching therapy is declining with newer agents
- Toxicity remains a principal reason for ARV switches
- Drug, patient and clinician factors are all important

Thanks to...

Dr Mark Nelson

Sonali Sonecha

Sundhiya Mandalia

Cristina Pacho

Sami Azzam

St Stephen's Aids Trust

Pharmacy Department, Chelsea and Westminster Hospital

